Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

554
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
554
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

665
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
665
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

250
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
250
Glaucoma: Overview01:25

Glaucoma: Overview

740
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
740

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Non-Infectious Choroiditis Subdivided into Its Diverse Pathophysiological Sub-Groups Is the Best-Known and Most Appropriate Nomenclature to Date for the Reclassification and Diagnosis of Former White Dot Entities.

Diagnostics (Basel, Switzerland)·2026
Same author

Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report.

The American journal of case reports·2026
Same author

The effect of improving cervical extension function on quality of life in patients with dropped head syndrome.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2026
Same author

Clinical performance of the multiplex solid-phase "Direct Strip PCR" for infectious uveitis: a multicenter diagnostic accuracy study.

Japanese journal of ophthalmology·2026
Same author

Tattoo-Associated Sarcoid-like Uveitis: A Multicenter Registry Study.

Biomedicines·2026
Same author

Necrotic-cell-activated macrophages drive an ERK-Bcl-xL survival pathway in osteoclasts and confer bisphosphonate resistance.

Biochemical and biophysical research communications·2026

関連する実験動画

Updated: Sep 9, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

早期のプロスタグランディン E1治療は,網膜中枢動脈閉塞の視覚的結果を改善する:後回顧的な研究

Hiroki Sano1, Ryoji Yanai2, Hirotaka Kondo1

  • 1Department of Ophthalmology, Tokushima Red Cross Hospital, Komatsushima, Japan.

Frontiers in ophthalmology
|September 5, 2025
PubMed
まとめ

中央網膜動脈閉塞 (CRAO) の患者では,プロスタグランジンE1 (PGE1) の早期治療により視力が有意に改善されました. これは,PGE1が網膜不全の緊急治療に有望であることを示唆しています.

キーワード:
中央網膜動脈の閉塞神経保護光学コヒーレンストモグラフィープロスタグランディンE1網膜不全 網膜不全視覚的な結果

さらに関連する動画

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.9K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K

関連する実験動画

Last Updated: Sep 9, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.9K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K

科学分野:

  • 眼科について
  • 血管医学
  • 薬理学について

背景:

  • 中央網膜動脈閉塞 (CRAO) は,突然の視力喪失を引き起こす重大な状態です.
  • CRAOの現在の治療法は有効性が証明されていない.
  • プロスタグランディンE1 (PGE1) は血管拡張性および細胞保護性特性を有しており,潜在的な治療効果を示しています.

研究 の 目的:

  • 中央網膜動脈閉塞 (CRAO) の患者の視力改善における早期の静脈内プロスタグランジンE1 (PGE1) 投与の有効性を評価する.
  • PGE1で治療されたCRAO患者の視覚の敏度と網膜の構造の変化を,従来の治療法と比較する.

主な方法:

  • 症状の発症から24時間以内にPGE1を静脈内投与したCRAO患者と経口投与を比較した遡及的研究.
  • 静脈内PGE1は5日間投与された.
  • 視覚の鋭さと網膜のパラメータ (最大網膜の厚さ,中央網膜の厚さ,動脈静脈直径) を評価し,PGE1と対照群を比較した.

主要な成果:

  • PGE1群は,対照群と比較して,一ヶ月後に顕著に改善された視覚の鋭さを示した.
  • グループ間で有意な網膜の厚さ (最大網膜の厚さ,中央網膜の厚さ) は観察されなかった.
  • PGE1 群の初期最大網膜の厚さは,1 ヶ月目の視力の低下と相関していました. 治療後の網膜動脈の直径は変化しなかった.

結論:

  • 静脈内プロスタグランジンE1 (PGE1) の早期投与は,中央網膜動脈閉塞 (CRAO) の患者の視力の回復を向上させるようです.
  • PGE1は,急性網膜不全症の有効な治療法として可能性を示しています.
  • これらの発見を確認し,CRAOの管理におけるPGE1の役割を確立するために,さらなる研究が必要である.